Certified Global Research Member
Isomar fd.webp Wcrc 57.webp
Key Questions Answered
  • Global Market Outlook
  • In-depth analysis of global and regional trends
  • Analyze and identify the major players in the market, their market share, key developments, etc.
  • To understand the capability of the major players based on products offered, financials, and strategies.
  • Identify disrupting products, companies, and trends.
  • To identify opportunities in the market.
  • Analyze the key challenges in the market.
  • Analyze the regional penetration of players, products, and services in the market.
  • Comparison of major players financial performance.
  • Evaluate strategies adopted by major players.
  • Recommendations
Why Choose Market Research Future?
  • Vigorous research methodologies for specific market.
  • Knowledge partners across the globe
  • Large network of partner consultants.
  • Ever-increasing/ Escalating data base with quarterly monitoring of various markets
  • Trusted by fortune 500 companies/startups/ universities/organizations
  • Large database of 5000+ markets reports.
  • Effective and prompt pre- and post-sales support.

US Anticoagulation Market


ID: MRFR/HC/12337-CR | 100 Pages | Author: Garvit Vyas| December 2023

In 2019, the North American anticoagulation market boasted a substantial market size, reaching USD 6,065.94 million, and it's projected to maintain a robust growth trajectory with an anticipated Compound Annual Growth Rate (CAGR) of 8.2% during the forecast period. Within North America, the market is segmented into the United States and Canada, with the region collectively holding the largest market share, accounting for 33.99% of the global market. This considerable market share can be attributed to several factors contributing to the rising demand for anticoagulation therapies. One significant driver is the increasing prevalence of conditions like venous thromboembolism (VTE) and cardiovascular disorders across the region. Additionally, there's a heightened risk of blood clot formation in various medical conditions prevalent in North America, further amplifying the need for effective anticoagulants. A pivotal contributing factor to the dominance of North America in the anticoagulation market is the widespread adoption of novel oral anticoagulants (NOACs) on a global scale. These NOACs have emerged as promising alternatives to traditional Vitamin K Antagonists (VKAs). However, it's important to note that their introduction into developing countries presents certain considerations and challenges. An article published in PubMed in 2016 highlights the complexities and obstacles associated with introducing NOACs in developing nations, indicating that while they offer promise, their implementation might face hurdles unique to these regions. The prominence of North America in the anticoagulation market signifies both its influence and the pressing healthcare needs within the region. The prevalence of conditions requiring anticoagulation therapy, coupled with the adoption of innovative treatment options like NOACs, positions North America as a frontrunner in driving advancements and shaping the global landscape of anticoagulation therapies. Overcoming the challenges associated with introducing novel treatments in diverse healthcare settings remains a crucial area for further exploration and development, ensuring equitable access and optimal care for patients worldwide. Furthermore, the growth of the anticoagulation market in North America is significantly bolstered by the active participation of major market players. These key players contribute to market expansion through continuous product innovation, strategic collaborations, and extensive expansion initiatives. Their proactive engagement fuels advancements within the sector, fostering a dynamic environment for growth and development. Moreover, the region benefits from a well-established healthcare infrastructure, which further augments the market's expansion and accessibility to innovative anticoagulation therapies.

Report Scope:
Report Attribute/Metric Details
  Market Size   2030 USD 20.54 Billion
  CAGR   7.50%
  Base Year   2020
  Forecast Period   2022-2030
  Historical Data   2021-2020
  Forecast Units   Value (USD Million)
  Report Coverage   Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
  Segments Covered   Technology,Application, and End Use
  Geographies Covered   North America, Europe, Asia-Pacific, and Rest of the World (RoW)
  Key Vendors   Pfizer Inc (US), Novartis AG (Switzerland),Sanofi (France),GlaxoSmithKline plc (UK),Daiichi Sankyo Company, Limited (Japan),Johnson & Johnson Services Inc (US),Boehringer Ingelheim International GmbH (Germany),Bristol-Myers Squibb Company (US),F. Hoffmann-La Roche Ltd (Switzerland),Portola Pharmaceuticals, Inc (US)
  Key Market Opportunities   Increase patient population and patent expiry to support new product launch
  Key Market Drivers   Rising incidence of cardiovascular and coronary artery diseases, growing awareness, expenditure, and dependence on anticoagulants.
 

Leading companies partner with us for data-driven Insights
client_1 client_2 client_3 client_4 client_5 client_6 client_7 client_8 client_9 client_10
Kindly complete the form below to receive a free sample of this Report
Please fill in Business Email for Quick Response

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

Purchase Option
Single User $ 4,950
Multiuser License $ 5,950
Enterprise User $ 7,250
Compare Licenses
Tailored for You
  • Dedicated Research on any specifics segment or region.
  • Focused Research on specific players in the market.
  • Custom Report based only on your requirements.
  • Flexibility to add or subtract any chapter in the study.
  • Historic data from 2014 and forecasts outlook till 2040.
  • Flexibility of providing data/insights in formats (PDF, PPT, Excel).
  • Provide cross segmentation in applicable scenario/markets.
  Related Reports
report-img
US Anticoagulation